Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Each lot of this antibody is quality control tested by ELISA assay. For ELISA Capture applications, the antibody should be titrated between 0.25 - 2 µg/ml to determine optimal condition. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Application Notes:
ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody. Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations. View intracellular cytokine staining protocol Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.
Application References:
1. Meager A, et al. 1984. J. Interferon Res. 4:619. 2. Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. 3. Sester M, et al. 2002. J. Virol. 76:3748. (FC) 4. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (FC) 5. Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) 6. Chen H, et al. 2005. J. Immunol. 175:591.(FC) 7. Smeltz RB, 2007. J. Immunol. 178:4786. (FC) 8. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed 9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
PMA/Ionomycin-stimulated human
PBMCs were stained with CD3
PE/Cy5 and 4S.B3 PE
Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
Other Names:
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Structure:
Cytokine; dimer; 20-25 kD (Mammalian)
Regulation:
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Cellular Sources:
CD8+ and CD4+ T cells, NK cells
Cellular Targets:
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors:
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Bioactivity/Activities:
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Antigen References:
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
PE anti-human IFN-γ
PMA/Ionomycin-stimulated human
PBMCs were stained with CD3
PE/Cy5 and 4S.B3 PE
APC anti-human IFN-γ
PMA/Ionomycin-stimulated human
PBMCs were stained with CD3
PE/Cy5 and 4S.B3 PE
FITC anti-human IFN-γ
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with mouse IgG1 FITC isotype control and CD3 (UCHT1) APC
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with 4S.B3 FITC and CD3 (UCHT1) APC
Biotin anti-human IFN-γ
Purified anti-human IFN-γ
PMA/Ionomycin-stimulated human
PBMCs were stained with CD3
PE/Cy5 and 4S.B3 PE
Alexa Fluor® 488 anti-human IFN-γ
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with mouse IgG1 Alexa Fluor® 488 isotype control and CD3 (UCHT1) APC
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with 4S.B3 Alexa Fluor® 488 and CD3 (UCHT1) APC
Alexa Fluor® 647 anti-human IFN-γ
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with mouse IgG1 Alexa Fluor® 647 isotype control and CD3 (UCHT1) PE
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with 4S.B3 Alexa Fluor® 647 and CD3 (UCHT1) PE
Alexa Fluor® 700 anti-human IFN-γ
PMA+ionomycin-stimulated (5 hours) human PBMCs surface stained with CD3 PE and intracellular stained with 4S.B3 Alexa Fluor® 700
Pacific Blue™ anti-human IFN-γ
PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellularly stained with 4S.B3 Pacific Blue™ and CD3 (HIT3a) PE
PerCP/Cy5.5 anti-human IFN-γ
PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellular stained with 4S.B3 PerCP/Cy5.5
APC/Cy7 anti-human IFN-γ
PMA+Ionomycin-stimulated human peripheral blood lymphocytes intracellularly stained with IFN-γ (4S.B3) APC/Cy7 and CD3 (OKT3) PE
PE/Cy7 anti-human IFN-γ
PMA/ionomycin-stimulated (5 hours) human peripheral blood lymphocytes intracellularly stained with 4S.B3 PE/Cy7 and CD4 (RPA-T4) PE
Brilliant Violet 421™ anti-human IFN-γ
Human peripheral blood lymphocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 FITC, fixed, permeabilized, and then stained with IFN-γ (clone 4S.B3) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
Brilliant Violet 570™ anti-human IFN-γ
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes were surface stained with CD3 FITC, and then intracellularly stained with IFN-γ (clone 4S.B3) Brilliant Violet 570™ (top) or mouse IgG1, κ Brilliant Violet 570™ isotype control (bottom).
Brilliant Violet 605™ anti-human IFN-γ
PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes were surface stained with CD3 FITC, and then intracellularly stained with IFN-γ (clone 4S.B3) Brilliant Violet 605™.
Brilliant Violet 650™ anti-human IFN-γ
PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes were surface stained with CD3 FITC, and then intracellularly stained with IFN-γ (clone 4S.B3) Brilliant Violet 650™.
